Presage Biosciences
Presage Biosciences develops a technology platform to improve the cancer drug development process.
Launch date
Employees
Market cap
-
Enterprise valuation
€25—38m (Dealroom.co estimates Mar 2021.)
Seattle Washington (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$8.0m | Debt | ||
$6.0m | Series D | ||
$6.0m | Series D | ||
$7.0m | Late VC | ||
$6.0m | Convertible | ||
| Total Funding | €26.4m | ||
Related Content
Recent News about Presage Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.